Transdermal estradiol/progesterone and glucose regulation in peri- and postmenopausal women with diabetes

Phase 4, open-label trial of estradiol and progesterone in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and menopause (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Time-in-range (TIR) for glucose over 14 days at end of treatment vs control period. Planned start Dec 2025; status: authorised.